1
|
Papadopoulos TG, Tripoliti EE, Plati D, Zelilidou S, Vlachos K, Konitsiotis S, Fotiadis DI. White Matter Lesion Segmentation for Multiple Sclerosis Patients implementing deep learning. Annu Int Conf IEEE Eng Med Biol Soc 2022; 2022:3818-3821. [PMID: 36085898 DOI: 10.1109/embc48229.2022.9871401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
The aim of this work is to address the problem of White Matter Lesion (WML) segmentation employing Magnetic Resonance Imaging (MRI) images from Multiple Sclerosis (MS) patients through the application of deep learning. A U-net based architecture containing a contrastive path and an expanding path prior to the final pixel-wise classification is implemented. The data are provided by the Ippokratio Radiology Center of Ioannina and include Fluid-Attenuated Inversion Recovery (FLAIR) MRI images from 30 patients in three phases, baseline and two follow ups. The prediction results are quite significant in terms of pixel-wise classification. The implemented deep learning model demonstrates Dice coefficient 0.7292, Precision 75.92% and Recall 70.16% in 2D slices of FLAIR MRI non-skull stripped images.
Collapse
|
2
|
Meinders MJ, Gentile G, Schrag AE, Konitsiotis S, Eggers C, Taba P, Lorenzl S, Odin P, Rosqvist K, Chaudhuri KR, Antonini A, Bloem BR, Groot MM. Advance Care Planning and Care Coordination for People With Parkinson's Disease and Their Family Caregivers-Study Protocol for a Multicentre, Randomized Controlled Trial. Front Neurol 2021; 12:673893. [PMID: 34434156 PMCID: PMC8382049 DOI: 10.3389/fneur.2021.673893] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2021] [Accepted: 06/30/2021] [Indexed: 11/13/2022] Open
Abstract
Background: Parkinson's disease (PD) is a progressive neurodegenerative disease with motor- and non-motor symptoms. When the disease progresses, symptom burden increases. Consequently, additional care demands develop, the complexity of treatment increases, and the patient's quality of life is progressively threatened. To address these challenges, there is growing awareness of the potential benefits of palliative care for people with PD. This includes communication about end-of-life issues, such as Advance Care Planning (ACP), which helps to elicit patient's needs and preferences on issues related to future treatment and care. In this study, we will assess the impact and feasibility of a nurse-led palliative care intervention for people with PD across diverse European care settings. Methods: The intervention will be evaluated in a multicentre, open-label randomized controlled trial, with a parallel group design in seven European countries (Austria, Estonia, Germany, Greece, Italy, Sweden and United Kingdom). The “PD_Pal intervention” comprises (1) several consultations with a trained nurse who will perform ACP conversations and support care coordination and (2) use of a patient-directed “Parkinson Support Plan-workbook”. The primary endpoint is defined as the percentage of participants with documented ACP-decisions assessed at 6 months after baseline (t1). Secondary endpoints include patients' and family caregivers' quality of life, perceived care coordination, patients' symptom burden, and cost-effectiveness. In parallel, we will perform a process evaluation, to understand the feasibility of the intervention. Assessments are scheduled at baseline (t0), 6 months (t1), and 12 months (t2). Statistical analysis will be performed by means of Mantel–Haenszel methods and multilevel logistic regression models, correcting for multiple testing. Discussion: This study will contribute to the current knowledge gap on the application of palliative care interventions for people with Parkinson's disease aimed at ameliorating quality of life and managing end-of-life perspectives. Studying the impact and feasibility of the intervention in seven European countries, each with their own cultural and organisational characteristics, will allow us to create a broad perspective on palliative care interventions for people with Parkinson's disease across settings. Clinical Trial Registration:www.trialregister.nl, NL8180.
Collapse
Affiliation(s)
- Marjan J Meinders
- Scientific Center for Quality of Healthcare, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands.,Department of Neurology, Center of Expertise for Parkinson and Movement Disorders, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, Netherlands
| | | | - Anette E Schrag
- Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, University College London, London, United Kingdom
| | - Spiros Konitsiotis
- Department of Neurology, Medical School, University of Ioannina, Ioannina, Greece
| | - Carsten Eggers
- Department of Neurology, Philipps University Marburg, Marburg, Germany.,Knappschaftskrankenhaus Bottrop GmbH, Department of Neurology, Bottrop, Germany
| | - Pille Taba
- Department of Neurology and Neurosurgery, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.,Neurology Clinic, Tartu University Hospital, Tartu, Estonia
| | - Stefan Lorenzl
- Institute of Nursing Science and Practice, Paracelsus Medical University, Salzburg, Austria.,Department of Neurology and Department of Palliative Care, Ludwig-Maximilians-University, Munich, Germany.,Department of Neurology, Klinikum Agatharied, Hausham, Germany
| | - Per Odin
- Division of Neurology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
| | - Kristina Rosqvist
- Division of Neurology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
| | - K Ray Chaudhuri
- Department of Basic and Clinical Neuroscience, Parkinson's Foundation Centre of Excellence, King's College London, London, United Kingdom
| | - Angelo Antonini
- Department of Neuroscience, University of Padua, Padua, Italy
| | - Bastiaan R Bloem
- Department of Neurology, Center of Expertise for Parkinson and Movement Disorders, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, Netherlands
| | - Marieke M Groot
- Department of Anesthesiology, Pain and Palliative Care, Radboud University Medical Center, Nijmegen, Netherlands
| |
Collapse
|
3
|
Kalogeropoulos D, Asproudis I, Stefaniotou M, Moschos M, Gartzonika C, Bassukas I, Konitsiotis S, Milionis H, Gaitanis G, Malamos K, Kalogeropoulos C. Spirochetal uveitis: Spectrum of clinical manifestations, diagnostic and therapeutic approach, final outcome and epidemiological data. Int Ophthalmol 2021; 41:4111-4126. [PMID: 34297303 DOI: 10.1007/s10792-021-01984-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Accepted: 07/16/2021] [Indexed: 11/28/2022]
Abstract
PURPOSE Analysis of cases with spirochetal uveitis related to spirochetes in a tertiary referral academic center. METHODS Retrospective study of patients diagnosed with uveitis attributed to Treponema pallidum, Leptospira spp. and Borrelia burgdorferi from June 1991 until December 2019. RESULTS A total of 57 cases of spirochetal uveitis (22 patients with T. pallidum, 26 with Leptospira spp., and 9 with B. burgdorferi) that consisted 1% of the overall number of uveitics were recorded. All these cases presented with a wide spectrum of clinical presentations (anterior uveitis, posterior uveitis, panuveitis, vasculitis, papillitis, and in some rare cases concomitant posterior scleritis). The treatment included mainly penicillin or doxycycline, while corticosteroids were administered systematically in some cases with Borrelia or Leptospira infection. The final visual outcome was favorable (> 6/10 in Snellen visual acuity) in approximately 76% of our patients. CONCLUSION Despite being rare, spirochetal uveitis can be detrimental for the vision and must always be included in the differential diagnosis.
Collapse
Affiliation(s)
- Dimitrios Kalogeropoulos
- Department of Ophthalmology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Stavros Niarchos Ave, 45500, Ioannina, Greece.
| | - Ioannis Asproudis
- Department of Ophthalmology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Stavros Niarchos Ave, 45500, Ioannina, Greece
| | - Maria Stefaniotou
- Department of Ophthalmology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Stavros Niarchos Ave, 45500, Ioannina, Greece
| | - Marilita Moschos
- 1St Department of Ophthalmology, General Hospital of Athens G. Gennimatas, Medical School, National and Kapodistrian University of Athens, Athens, Greece
| | - Constantina Gartzonika
- Laboratory of Microbiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
| | - Ioannis Bassukas
- Department of Skin & Venereal Diseases, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
| | - Spiros Konitsiotis
- Department of Neurology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
| | - Haralampos Milionis
- 1St Division of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
| | - Georgios Gaitanis
- Department of Skin & Venereal Diseases, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
| | - Konstantinos Malamos
- Department of Ophthalmology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Stavros Niarchos Ave, 45500, Ioannina, Greece
| | - Chris Kalogeropoulos
- Department of Ophthalmology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Stavros Niarchos Ave, 45500, Ioannina, Greece
| |
Collapse
|
4
|
Kostikis N, Rigas G, Tachos N, Konitsiotis S, Fotiadis DI. On-Body Sensor Position Identification with a Simple, Robust and Accurate Method, Validated in Patients with Parkinson's Disease. Annu Int Conf IEEE Eng Med Biol Soc 2020; 2020:4156-4159. [PMID: 33018913 DOI: 10.1109/embc44109.2020.9175913] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
The aim of this work is to implement and validate an automated method for the localization of body-worn inertial sensors. Often, body-sensor networks with inertial measurement units (IMU) used in rehabilitation and ambient monitoring of patients with movement disorders, require specific markings or labels for the correct body placement. This introduces a burden, which, especially for ambient monitoring, could lead to errors or reduced adherence. We propose a method to automatically identify sensors attached on a predefined set of body placements, namely, wrists, shanks and torso. The method was used in a multi-site clinical trial with Parkinson's disease patients and in 45 sessions it identified sensor placement on torso, wrists and shanks with 100% accuracy, discriminated between left and right shank with 100% accuracy and between left and right wrist with 98% accuracy. This is remarkable, considering the presence of parkinsonian motor symptoms causing abnormal movement patterns, such as dyskinesia.Clinical Relevance- This method can facilitate home monitoring of patients with movement disorders.
Collapse
|
5
|
Timotijevic L, Hodgkins CE, Banks A, Rusconi P, Egan B, Peacock M, Seiss E, Touray MML, Gage H, Pellicano C, Spalletta G, Assogna F, Giglio M, Marcante A, Gentile G, Cikajlo I, Gatsios D, Konitsiotis S, Fotiadis D. Designing a mHealth clinical decision support system for Parkinson's disease: a theoretically grounded user needs approach. BMC Med Inform Decis Mak 2020; 20:34. [PMID: 32075633 PMCID: PMC7031960 DOI: 10.1186/s12911-020-1027-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Accepted: 01/20/2020] [Indexed: 11/13/2022] Open
Abstract
Background Despite the established evidence and theoretical advances explaining human judgments under uncertainty, developments of mobile health (mHealth) Clinical Decision Support Systems (CDSS) have not explicitly applied the psychology of decision making to the study of user needs. We report on a user needs approach to develop a prototype of a mHealth CDSS for Parkinson’s disease (PD), which is theoretically grounded in the psychological literature about expert decision making and judgement under uncertainty. Methods A suite of user needs studies was conducted in 4 European countries (Greece, Italy, Slovenia, the UK) prior to the development of PD_Manager, a mHealth-based CDSS designed for Parkinson’s disease, using wireless technology. Study 1 undertook Hierarchical Task Analysis (HTA) including elicitation of user needs, cognitive demands and perceived risks/benefits (ethical considerations) associated with the proposed CDSS, through structured interviews of prescribing clinicians (N = 47). Study 2 carried out computational modelling of prescribing clinicians’ (N = 12) decision strategies based on social judgment theory. Study 3 was a vignette study of prescribing clinicians’ (N = 18) willingness to change treatment based on either self-reported symptoms data, devices-generated symptoms data or combinations of both. Results Study 1 indicated that system development should move away from the traditional silos of ‘motor’ and ‘non-motor’ symptom evaluations and suggest that presenting data on symptoms according to goal-based domains would be the most beneficial approach, the most important being patients’ overall Quality of Life (QoL). The computational modelling in Study 2 extrapolated different factor combinations when making judgements about different questions. Study 3 indicated that the clinicians were equally likely to change the care plan based on information about the change in the patient’s condition from the patient’s self-report and the wearable devices. Conclusions Based on our approach, we could formulate the following principles of mHealth design: 1) enabling shared decision making between the clinician, patient and the carer; 2) flexibility that accounts for diagnostic and treatment variation among clinicians; 3) monitoring of information integration from multiple sources. Our approach highlighted the central importance of the patient-clinician relationship in clinical decision making and the relevance of theoretical as opposed to algorithm (technology)-based modelling of human judgment.
Collapse
Affiliation(s)
- L Timotijevic
- Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
| | - C E Hodgkins
- Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
| | - A Banks
- Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
| | - P Rusconi
- Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
| | - B Egan
- Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
| | - M Peacock
- Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
| | - E Seiss
- Department of Psychology, University of Bournemouth, Bournemouth, UK
| | - M M L Touray
- Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
| | - H Gage
- Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
| | - C Pellicano
- Department of Neurorehabilitation, Fondanzione Santa Lucia, Rome, Italy
| | - G Spalletta
- Department of Neurorehabilitation, Fondanzione Santa Lucia, Rome, Italy
| | - F Assogna
- Department of Neurorehabilitation, Fondanzione Santa Lucia, Rome, Italy
| | - M Giglio
- Fondanzione Ospedale San Camillo (I.R.C.C.S.), Parkinson's Department Institute of Neurology, Venice, Italy
| | - A Marcante
- Fondanzione Ospedale San Camillo (I.R.C.C.S.), Parkinson's Department Institute of Neurology, Venice, Italy
| | - G Gentile
- Fondanzione Ospedale San Camillo (I.R.C.C.S.), Parkinson's Department Institute of Neurology, Venice, Italy
| | - I Cikajlo
- University Rehabilitation Institute, Republic of Slovenia, Soča, Ljubljana, Slovenia
| | - D Gatsios
- Department of Material Sciences and Engineering, University of Ioannina, Ioannina, Greece
| | - S Konitsiotis
- Nurology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
| | - D Fotiadis
- Department of Material Sciences and Engineering, University of Ioannina, Ioannina, Greece
| |
Collapse
|
6
|
Tsiouris KM, Konitsiotis S, Koutsouris DD, Fotiadis DI. Prognostic factors of Rapid symptoms progression in patients with newly diagnosed parkinson's disease. Artif Intell Med 2020; 103:101807. [PMID: 32143804 DOI: 10.1016/j.artmed.2020.101807] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2019] [Revised: 01/07/2020] [Accepted: 01/13/2020] [Indexed: 10/25/2022]
Abstract
Tracking symptoms progression in the early stages of Parkinson's disease (PD) is a laborious endeavor as the disease can be expressed with vastly different phenotypes, forcing clinicians to follow a multi-parametric approach in patient evaluation, looking for not only motor symptomatology but also non-motor complications, including cognitive decline, sleep problems and mood disturbances. Being neurodegenerative in nature, PD is expected to inflict a continuous degradation in patients' condition over time. The rate of symptoms progression, however, is found to be even more chaotic than the vastly different phenotypes that can be expressed in the initial stages of PD. In this work, an analysis of baseline PD characteristics is performed using machine learning techniques, to identify prognostic factors for early rapid progression of PD symptoms. Using open data from the Parkinson's Progression Markers Initiative (PPMI) study, an extensive set of baseline patient evaluation outcomes is examined to isolate determinants of rapid progression within the first two and four years of PD. The rate of symptoms progression is estimated by tracking the change of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) total score over the corresponding follow-up period. Patients are ranked according to their progression rates and those who expressed the highest rates of MDS-UPDRS total score increase per year of follow-up period are assigned into the rapid progression class, using 5- and 10-quantiles partition. Classification performance against the rapid progression class was evaluated in a per quantile partition analysis scheme and in quantile-independent approach, respectively. The results shown a more accurate patient discrimination with quantile partitioning, however, a much more compact subset of baseline factors is extracted in the latter, making a more suitable for actual interventions in practice. Classification accuracy improved in all cases when using the longer 4-year follow-up period to estimate PD progression, suggesting that a prolonged patient evaluation can provide better outcomes in identifying rapid progression phenotype. Non-motor symptoms are found to be the main determinants of rapid symptoms progression in both follow-up periods, with autonomic dysfunction, mood impairment, anxiety, REM sleep behavior disorders, cognitive decline and memory impairment being alarming signs at baseline evaluation, along with rigidity symptoms, certain laboratory blood test results and genetic mutations.
Collapse
Affiliation(s)
- Kostas M Tsiouris
- Biomedical Engineering Laboratory, School of Electrical and Computer Engineering, National Technical University of Athens, GR15773, Athens, Greece; Unit of Medical Technology and Intelligent Information Systems, Dept. of Material Science and Engineering, University of Ioannina, GR45110, Ioannina, Greece
| | - Spiros Konitsiotis
- Dept. of Neurology, Medical School, University of Ioannina, GR45110, Ioannina, Greece
| | - Dimitrios D Koutsouris
- Biomedical Engineering Laboratory, School of Electrical and Computer Engineering, National Technical University of Athens, GR15773, Athens, Greece
| | - Dimitrios I Fotiadis
- Unit of Medical Technology and Intelligent Information Systems, Dept. of Material Science and Engineering, University of Ioannina, GR45110, Ioannina, Greece; Dept. of Biomedical Research, Institute of Molecular Biology and Biotechnology, FORTH, GR45110, Ioannina, Greece.
| |
Collapse
|
7
|
Tsiouris ΚΜ, Pezoulas VC, Zervakis M, Konitsiotis S, Koutsouris DD, Fotiadis DI. A Long Short-Term Memory deep learning network for the prediction of epileptic seizures using EEG signals. Comput Biol Med 2018; 99:24-37. [DOI: 10.1016/j.compbiomed.2018.05.019] [Citation(s) in RCA: 272] [Impact Index Per Article: 45.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2018] [Revised: 05/07/2018] [Accepted: 05/16/2018] [Indexed: 11/24/2022]
|
8
|
Tsiouris KM, Konitsiotis S, Markoula S, Koutsouris DD, Fotiadis DI. An Unsupervised Methodology for the Detection of Epileptic Seizures Using EEG Signals: A Multi-Dataset Evaluation. Annu Int Conf IEEE Eng Med Biol Soc 2018; 2018:3390-3393. [PMID: 30441115 DOI: 10.1109/embc.2018.8513079] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Although the electroencephalogram (EEG) is the most commonly used means to monitor epileptic patients, public EEG datasets are very scarce making it difficult to develop and validate seizure detection algorithms. In this work an unsupervised seizure detection methodology is used to isolate ictal EEG segments without requiring any apriori information or human intervention. Seizures are detected using four simple seizure detection conditions that are activated when rhythmical activity from different brain areas is simultaneously concentrated in the alpha (8-13 Hz), theta (4-7 Hz) or delta (1-3 Hz) frequency range. Then, only a small proportion of the EEG segments that are most likely to contain ictal activity is selected and presented to the physician for the final evaluation. In this way, large volumes of EEG signals can be annotated in a fraction of the time and effort that would be otherwise required. Using EEG data from 33 sessions from the Temple University Hospital (TUH) EEG Corpus, our unsupervised methodology reached, on average, 84.92% seizure detection sensitivity with 3.46 false detections per hour of EEG signals.
Collapse
|
9
|
Valmarska A, Miljkovic D, Konitsiotis S, Gatsios D, Lavrač N, Robnik-Šikonja M. Symptoms and medications change patterns for Parkinson's disease patients stratification. Artif Intell Med 2018; 91:82-95. [PMID: 29803610 DOI: 10.1016/j.artmed.2018.04.010] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Revised: 04/26/2018] [Accepted: 04/30/2018] [Indexed: 12/26/2022]
Abstract
Quality of life of patients with Parkinson's disease degrades significantly with disease progression. This paper presents a step towards personalized management of Parkinson's disease patients, based on discovering groups of similar patients. Similarity is based on patients' medical conditions and changes in the prescribed therapy when the medical conditions change. We present two novel approaches. The first algorithm discovers symptoms' impact on Parkinson's disease progression. Experiments on the Parkinson Progression Markers Initiative (PPMI) data reveal a subset of symptoms influencing disease progression which are already established in Parkinson's disease literature, as well as symptoms that are considered only recently as possible indicators of disease progression by clinicians. The second novelty is a methodology for detecting patterns of medications dosage changes based on the patient status. The methodology combines multitask learning using predictive clustering trees and short time series analysis to better understand when a change in medications is required. The experiments on PPMI data demonstrate that, using the proposed methodology, we can identify some clinically confirmed patients' symptoms suggesting medications change. In terms of predictive performance, our multitask predictive clustering tree approach is mostly comparable to the random forest multitask model, but has the advantage of model interpretability.
Collapse
Affiliation(s)
- Anita Valmarska
- Jožef Stefan Institute, Jamova 39, Ljubljana, Slovenia; Jožef Stefan International Postgraduate School, Jamova 39, Ljubljana, Slovenia.
| | | | - Spiros Konitsiotis
- University of Ioannina, Medical School, Department of Neurology, Ioannina, Greece.
| | - Dimitris Gatsios
- University of Ioannina, Department of Biomedical Research, Ioannina, Greece.
| | - Nada Lavrač
- Jožef Stefan Institute, Jamova 39, Ljubljana, Slovenia; Jožef Stefan International Postgraduate School, Jamova 39, Ljubljana, Slovenia.
| | | |
Collapse
|
10
|
Tzallas AT, Karvelis PS, Katsis CD, Giannopoulos S, Konitsiotis S, Fotiadis DI. A Method for Classification of Transient Events in EEG Recordings: Application to Epilepsy Diagnosis. Methods Inf Med 2018. [DOI: 10.1055/s-0038-1634122] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Summary
Objectives:
The aim of the paper is to analyze transient events in inter-ictal EEG recordings, and classify epileptic activity into focal or generalized epilepsy using an automated method.
Methods:
A two-stage approach is proposed. In the first stage the observed transient events of a single channel are classified into four categories: epileptic spike (ES), muscle activity (EMG), eye blinking activity (EOG), and sharp alpha activity (SAA). The process is based on an artificial neural network. Different artificial neural network architectures have been tried and the network having the lowest error has been selected using the hold out approach. In the second stage a knowledge-based system is used to produce diagnosis for focal or generalized epileptic activity.
Results:
The classification of transient events reported high overall accuracy (84.48%), while the knowledge-based system for epilepsy diagnosis correctly classified nine out of ten cases.
Conclusions:
The proposed method is advantageous since it effectively detects and classifies the undesirable activity into appropriate categories and produces a final outcome related to the existence of epilepsy.
Collapse
|
11
|
Tsiouris ΚΜ, Markoula S, Konitsiotis S, Koutsouris DD, Fotiadis DI. A robust unsupervised epileptic seizure detection methodology to accelerate large EEG database evaluation. Biomed Signal Process Control 2018. [DOI: 10.1016/j.bspc.2017.09.029] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Katsanos AH, Kosmidou M, Konitsiotis S, Tsivgoulis G, Fiolaki A, Kyritsis AP, Giannopoulos S. Restless legs syndrome and cerebrovascular/cardiovascular events: Systematic review and meta-analysis. Acta Neurol Scand 2018; 137:142-148. [PMID: 28948600 DOI: 10.1111/ane.12848] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/11/2017] [Indexed: 01/26/2023]
Abstract
OBJECTIVE We performed a systematic review and meta-analysis to evaluate the proposed association of restless legs syndrome (RLS) with cerebrovascular/cardiovascular outcomes. METHODS We calculated the corresponding odds ratios on the prevalence of cerebrovascular/cardiovascular risk factors and standardized mean differences on the reported mean age at baseline between RLS patients and controls. We also calculated the corresponding risk ratios and adjusted for potential confounders hazard ratios (HRsadjusted ) on the reported outcomes of interest between RLS patients and controls. RESULTS We identified 8 eligible studies (644 506 patients, mean age: 60.2 years, 36.2% males; 3.3% with RLS). RLS patients were found to have significantly higher prevalence of hypertension (P = .002), diabetes (P = .003) and hyperlipidemia (P = .010) compared to controls. In the unadjusted analyses of prospective observational studies, RLS patients were found to have significantly higher risk for cerebrovascular ischaemia (P = .01) and all-cause mortality (P = .04) compared to controls during follow-up, while in the adjusted for potential confounders analyses RLS patients were only found to have a higher risk of all-cause mortality (HR adjusted=1.52, 95% CI: 1.17-1.97, P = .002). CONCLUSIONS The present report does not provide evidence for an increased risk of cerebrovascular and cardiovascular events in RLS patients, which highlights the vast presence of confounding factors.
Collapse
Affiliation(s)
- A. H. Katsanos
- Department of Neurology; School of Medicine; University of Ioannina; Ioannina Greece
- Neurosurgical Research Institute; University of Ioannina; Ioannina Greece
| | - M. Kosmidou
- Department of Internal Medicine; School of Medicine; University of Ioannina; Ioannina Greece
| | - S. Konitsiotis
- Department of Neurology; School of Medicine; University of Ioannina; Ioannina Greece
| | - G. Tsivgoulis
- Second Department of Neurology; School of Medicine; University of Athens; Athens Greece
- Department of Neurology; University of Tennessee Health Science Center; Memphis TN USA
| | - A. Fiolaki
- Department of Neurology; School of Medicine; University of Ioannina; Ioannina Greece
| | - A. P. Kyritsis
- Department of Neurology; School of Medicine; University of Ioannina; Ioannina Greece
- Neurosurgical Research Institute; University of Ioannina; Ioannina Greece
| | - S. Giannopoulos
- Department of Neurology; School of Medicine; University of Ioannina; Ioannina Greece
- Neurosurgical Research Institute; University of Ioannina; Ioannina Greece
| |
Collapse
|
13
|
Tsiouris KM, Rigas G, Gatsios D, Antonini A, Konitsiotis S, Koutsouris DD, Fotiadis DI. Predicting rapid progression of Parkinson's Disease at baseline patients evaluation. Annu Int Conf IEEE Eng Med Biol Soc 2017; 2017:3898-3901. [PMID: 29060749 DOI: 10.1109/embc.2017.8037708] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
The rate of Parkinson's Disease (PD) progression in the initial post-diagnosis years can vary significantly. In this work, a methodology for the extraction of the most informative features for predicting rapid progression of the disease is proposed, using public data from the Parkinson's Progression Markers Initiative (PPMI) and machine learning techniques. The aim is to determine if a patient is at risk of expressing rapid progression of PD symptoms from the baseline evaluation and as close to diagnosis as possible. By examining the records of 409 patients from the PPMI dataset, the features with the best predictive value at baseline patient evaluation are found to be sleep problems, daytime sleepiness and fatigue, motor symptoms at legs, cognition impairment, early axial and facial symptoms and in the most rapidly advanced cases speech issues, loss of smell and affected leg muscle reflexes.
Collapse
|
14
|
Valmarska A, Miljkovic D, Konitsiotis S, Gatsios D, Lavrač N, Robnik-Šikonja M. Combining Multitask Learning and Short Time Series Analysis in Parkinson’s Disease Patients Stratification. Artif Intell Med 2017. [DOI: 10.1007/978-3-319-59758-4_13] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
15
|
Lakatos A, Kosta P, Konitsiotis S, Zikou AK, Astrakas LG, Argyropoulou MI. Marchiafava-Bignami disease: An acquired callosotomy. Neurology 2014; 83:1219. [DOI: 10.1212/wnl.0000000000000811] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
16
|
Chondrogiorgi M, Tatsioni A, Reichmann H, Konitsiotis S. Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials. Eur J Neurol 2013; 21:433-40. [PMID: 24313869 DOI: 10.1111/ene.12318] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2013] [Accepted: 10/21/2013] [Indexed: 11/30/2022]
Abstract
BACKGROUND AND PURPOSE Dopamine agonists (DAs) are generally considered to be deprived of the highly dyskinetic effect of levodopa in Parkinson's disease (PD) patients. However, the risk for dyskinesia induced by DA monotherapy and the contribution of clinically significant factors in the development of this disorder have never been systematically assessed. METHODS A systematic literature search was conducted for randomized, levodopa-controlled trials of DAs in early PD. A meta-analysis was performed to calculate the combined odds ratio (OR) for dyskinesia. Meta-regressions were subsequently performed on dyskinesia OR including individually as covariates the effects of mean disease duration, treatment duration and DA dose. In an additional analysis the effect of adjunct levodopa on the odds for dyskinesia was investigated. RESULTS DA monotherapy resulted in an 87% lower risk for dyskinesia compared with treatment with levodopa (OR = 0.13, 95% confidence interval 0.09-0.19, P < 0.001). The risk for dyskinesia was independent of the dose of DA, disease duration and treatment duration. A dose-related pattern was revealed between adjunct levodopa in the DA group and dyskinesia. Nevertheless, the odds for dyskinesia in the DA group were constantly lower than in the levodopa group. CONCLUSION Initial DA treatment encompasses a lower risk for dyskinesia even after the unavoidable introduction of levodopa that increases the risk for dyskinesia in a dose-related manner. As the dose and treatment duration with DAs are factors independent of the risk of dyskinesia, monotherapy with DAs in early PD is suggested at doses that ensure efficacy and delay the need for levodopa, always following an adequate evaluation of the risks DAs can pose in individual patients.
Collapse
Affiliation(s)
- M Chondrogiorgi
- Department of Neurology, University of Ioannina, Ioannina, Greece
| | | | | | | |
Collapse
|
17
|
Tzarouchi LC, Zikou AK, Tsifetaki N, Astrakas LG, Konitsiotis S, Voulgari P, Drosos A, Argyropoulou MI. White matter water diffusion changes in primary Sjögren syndrome. AJNR Am J Neuroradiol 2013; 35:680-5. [PMID: 24184520 DOI: 10.3174/ajnr.a3756] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
BACKGROUND AND PURPOSE Histopathologic studies have demonstrated WM damage in primary Sjögren syndrome. The purpose of this study was to evaluate WM microstructural changes by use of DTI-derived parameters in patients with primary Sjögren syndrome. MATERIALS AND METHODS DTI was performed in 19 patients with primary Sjögren syndrome (age, 64.73 ± 9.1 years; disease duration, 11.5 ± 7.56 years) and 16 age-matched control subjects. Exclusion criteria were a history of major metabolic, neurologic, or psychiatric disorder and high risk for cardiovascular disease. Data were analyzed by use of tract-based spatial statistics, for which the WM skeleton was created, and a permutation-based inference with 5000 permutations was used with a threshold of P < .01, corrected for multiple comparisons to enable identification of abnormalities in fractional anisotropy, mean diffusivity, radial diffusivity, and axial diffusivity. RESULTS Tract-based spatial statistics showed decreased fractional anisotropy in multiple areas in patients with primary Sjögren syndrome compared with control subjects, located mainly in the corticospinal tract, superior longitudinal fasciculus, anterior thalamic radiation, inferior fronto-occipital fasciculus, uncinate fasciculus, and inferior longitudinal fasciculus. Increased mean diffusivity and radial diffusivity and decreased axial diffusivity were observed in most of the fiber tracts of the brain in patients with primary Sjögren syndrome, compared with control subjects. CONCLUSIONS Patients with primary Sjögren syndrome show loss of WM microstructural integrity, probably related to both Wallerian degeneration and demyelination.
Collapse
Affiliation(s)
- L C Tzarouchi
- From the Departments of Radiology (L.C.T., A.K.Z., M.I.A.)
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Kastanioudakis I, Konitsiotis S, Asproudis I, Ziavra N. Venous pulsatile tinnitus due to pseudotumor cerebri syndrome in a young morbid obese female. Hippokratia 2013; 17:383. [PMID: 25031526 PMCID: PMC4097428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Affiliation(s)
- I Kastanioudakis
- Department of Otorhinolaryngology, University of Ioannina, Ioannina, Greece
| | - S Konitsiotis
- Department of Neurology, University of Ioannina, Ioannina, Greece
| | - I Asproudis
- Department of Ophthalmology, University of Ioannina, Ioannina, Greece
| | - N Ziavra
- Speech and Language Therapy Department, TEI of Epirus, Ioannina, Greece
| |
Collapse
|
19
|
Kaltsonoudis E, Papagoras C, Konitsiotis S, Markatseli T, Zikou A, Argyropoulou M, Drosos A. AB1251 Neurological manifestations associated with anti-tumor necrosis factor alpha treatment. A longitudinal study. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.1247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
20
|
Stathis P, Smpiliris M, Konitsiotis S, Mitsikostas DD. Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta‐analysis. Eur J Neurol 2012; 20:527-533. [DOI: 10.1111/ene.12014] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2012] [Accepted: 09/17/2012] [Indexed: 12/19/2022]
Affiliation(s)
- P. Stathis
- Neurology Department Sismanoglion Hospital AthensGreece
| | - M. Smpiliris
- Neurology Department Sismanoglion Hospital AthensGreece
| | - S. Konitsiotis
- Neurology Department University of Ioannina IoanninaGreece
| | | |
Collapse
|
21
|
Tsipouras MG, Tzallas AT, Rigas G, Tsouli S, Fotiadis DI, Konitsiotis S. An automated methodology for levodopa-induced dyskinesia: assessment based on gyroscope and accelerometer signals. Artif Intell Med 2012; 55:127-35. [PMID: 22484102 DOI: 10.1016/j.artmed.2012.03.003] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2010] [Revised: 02/23/2012] [Accepted: 03/04/2012] [Indexed: 11/18/2022]
Abstract
OBJECTIVE In this study, a methodology is presented for an automated levodopa-induced dyskinesia (LID) assessment in patients suffering from Parkinson's disease (PD) under real-life conditions. METHODS AND MATERIAL The methodology is based on the analysis of signals recorded from several accelerometers and gyroscopes, which are placed on the subjects' body while they were performing a series of standardised motor tasks as well as voluntary movements. Sixteen subjects were enrolled in the study. The recordings were analysed in order to extract several features and, based on these features, a classification technique was used for LID assessment, i.e. detection of LID symptoms and classification of their severity. RESULTS The results were compared with the clinical annotation of the signals, provided by two expert neurologists. The analysis was performed related to the number and topology of sensors used; several different experimental settings were evaluated while a 10-fold stratified cross validation technique was employed in all cases. Moreover, several different classification techniques were examined. The ability of the methodology to be generalised was also evaluated using leave-one-patient-out cross validation. The sensitivity and positive predictive values (average for all LID severities) were 80.35% and 76.84%, respectively. CONCLUSIONS The proposed methodology can be applied in real-life conditions since it can perform LID assessment in recordings which include various PD symptoms (such as tremor, dyskinesia and freezing of gait) of several motor tasks and random voluntary movements.
Collapse
Affiliation(s)
- Markos G Tsipouras
- Unit of Medical Technology and Intelligent Information Systems, Dept. of Materials Science and Engineering, University of Ioannina, GR 45110 Ioannina, Greece
| | | | | | | | | | | |
Collapse
|
22
|
Margariti PN, Astrakas LG, Tsouli SG, Hadjigeorgiou GM, Konitsiotis S, Argyropoulou MI. Investigation of unmedicated early onset restless legs syndrome by voxel-based morphometry, T2 relaxometry, and functional MR imaging during the night-time hours. AJNR Am J Neuroradiol 2011; 33:667-72. [PMID: 22173758 DOI: 10.3174/ajnr.a2829] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
BACKGROUND AND PURPOSE The pathophysiology of eRLS has not yet been elucidated. The purpose of the study was to assess, in patients with eRLS, the volume, iron content, and activation of the brain during night-time episodes of SLD and PLMs. MATERIALS AND METHODS Eleven right-handed unmedicated patients with eRLS (mean age, 55.3 ± 8.4 years; disease duration, 17.5 ± 14.05 years) and 11 matched control subjects were studied with a T1-weighted high-resolution 3D spoiled gradient-echo sequence used for VBM and a multisection spin-echo T2-weighted sequence used for T2 relaxometry. Additionally, a single-shot multisection gradient echo-planar sequence was used for fMRI. Brain activation was recorded during spontaneous SLD and PLMs. SPM software was used for analysis of the functional data. RESULTS The patients showed no regional brain volume change, but T2 relaxometry revealed decreased T2 relaxation time in the right globus pallidus internal and the STN, indicating increased iron content. The patients were observed to activate the following areas: in the left hemisphere, the primary motor and somatosensory cortex, the thalamus, the pars opercularis, and the ventral anterior cingulum; and in the right hemisphere, the striatum, the inferior and superior parietal lobules, and the dorsolateral prefrontal cortex. Bilateral activation was observed in the cerebellum, the midbrain, and the pons. CONCLUSIONS eRLS is associated with increased iron content of the globus pallidus internal and STN, suggesting dysfunction of the basal ganglia. Activation of the striatofrontolimbic area may represent the neurofunctional substrate mediating the repetitive compulsive movements seen in RLS.
Collapse
Affiliation(s)
- P N Margariti
- Department of Radiology, Medical School, University of Ioannina, Ioannina, Greece
| | | | | | | | | | | |
Collapse
|
23
|
Maranis S, Tsouli S, Konitsiotis S. Treatment of motor symptoms in advanced Parkinson's disease: a practical approach. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:1795-807. [PMID: 21645577 DOI: 10.1016/j.pnpbp.2011.05.014] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2011] [Revised: 03/29/2011] [Accepted: 05/23/2011] [Indexed: 12/28/2022]
Abstract
Patients with advanced Parkinson's disease (PD) are known to develop motor complications after a few years of levodopa (L-dopa) therapy. Motor fluctuations develop with increasing severity of the disease, owing to loss of dopaminergic neurons and loss of the buffering capacity of the neurons to fluctuating dopamine levels. Dyskinesias develop as a result of pulsatile stimulation of the receptors and alterations in neuronal firing patterns. L-dopa remains the gold standard medication for the treatment of patients with advanced PD. However, once motor complications on L-dopa therapy emerge, clinicians may add on other classes of antiparkinsonian drugs such as dopamine agonists, catechol-O-methyl transferase inhibitors (COMTIs) or monoamine oxidase type B inhibitors (MAOBIs). The individualisation of the treatment seems to be the key for the best approach of advanced PD patients. The present review provides the most important current clinical data in the pharmacological treatment of motor symptoms in advanced PD and provides the clinician a simple algorithm in order to determine the best suitable treatment to advanced parkinsonian patients.
Collapse
Affiliation(s)
- S Maranis
- Department of Neurology, University Hospital of Ioannina, Greece
| | | | | |
Collapse
|
24
|
Stathis P, Konitsiotis S, Tagaris G, Peterson D. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2010; 26:264-70. [PMID: 21412833 DOI: 10.1002/mds.23355] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2010] [Revised: 03/10/2010] [Accepted: 06/23/2010] [Indexed: 11/11/2022] Open
Abstract
The efficacy and safety of levetiracetam (LEV), administered for management of levodopa-induced dyskinesias (LID) in Parkinson's disease (PD), was examined using a multicenter, double-blind, placebo-controlled, parallel groups, crossover trial. Because of having a period effect, data after crossover point was excluded from analysis. Levodopa-treated PD participants with LID (n = 38) received LEV 500 mg/day, were assessed, titrated to 1,000 mg/day and reassessed, before and after crossover. The placebo group followed the same routine. Primary efficacy was defined from percent change in "On with LID" time from patient diaries. Secondary efficacy assessment used "On without LID," "Off" time, unified PD rating scale (UPDRS), clinical global impression (CGI), and Goetz dyskinesia scale after levodopa challenge. Safety measures were also performed. On with LID time decreased 37 minutes (95% confidence interval [CI] 0.59, 7.15; P = 0.02) at 500 mg/day, 7.85% 75 minutes (95% CI 3.3, 12.4; P = 0.002) at 1,000 mg/day. On without LID time increased by 46 minutes (95% CI -1.55, -0.03; P = 0.04) at 500 mg/day and 55 minutes (95% CI -10.39, -1.14; P = 0.018) at 1,000 mg/day. UPDRS 32 showed decreased dyskinesia duration mean change 0.35 (95% CI 0.09, 0.5; P = 0.009) at 1,000 mg/day. CGI showed LID decreased by 0.7 (95% CI 0.21, 1.18; P = 0.006) at 1,000 mg/day. Patient diaries and UPDRS show no increase in Off time. This exploratory trial provides evidence that LEV in 1,000 mg/day, slowly titrated, could be useful in improving LID as was assessed with patient diaries, UPDRS, and CGI scales, safely, with minimal side effects.
Collapse
Affiliation(s)
- P Stathis
- Department of Neurology, 1st Hospital of Social Security Services, Athens, Greece.
| | | | | | | | | |
Collapse
|
25
|
Abstract
Parkinson's disease (PD) is characterised by the progressive degeneration of dopaminergic nigro-striatal neurons and severe striatal dopaminergic deficiency, leading to bradykinesia. Levodopa was the first drug used for PD treatment and is still considered the most useful weapon for the control of PD symptoms. However, levodopa treatment induces motor complications, which is considered as a major problem as the disease progresses. Dopamine agonists, catechol-O-methyltransferase inhibitors and monoamine oxidase B inhibitors are some more recently developed drug categories which are expected to have a more favourable effect on motor complications. The choice of the best initial treatment in PD remains a controversial matter. Early therapeutic decisions in PD should balance the need for efficient short-term symptom control against long-term complication profile. The individualisation of the treatment seems to be the key for the best approach of early PD patients.
Collapse
Affiliation(s)
- S Tsouli
- Department of Neurology, University Hospital of Ioannina, Ioannina, Greece.
| | | |
Collapse
|
26
|
Rigas G, Tzallas AT, Tsalikakis DG, Konitsiotis S, Fotiadis DI. Real-time quantification of resting tremor in the Parkinson's disease. Annu Int Conf IEEE Eng Med Biol Soc 2010; 2009:1306-9. [PMID: 19963494 DOI: 10.1109/iembs.2009.5332580] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Resting tremor (RT) is one of the most frequent signs of the Parkinson's disease (PD), occurring with various severities in about 75% of the patients. Current diagnosis is based on subjective clinical assessment, which is not always easy to capture subtle, mild and intermittent tremors. The aim of the present study is to assess the suitability and clinical value of a computer based real-time system as an aid to diagnosis of PD, in particular the presence of RT. Five healthy subjects were asked to simulate several severities of RT in hands and feet in three static activities. The behaviour of the subjects is measured using tri-axial accelerometers, which are placed at four different positions on the body. Frequency-domain features, strongly correlated with the RT activity, are extracted from the accelerometer data. The classification of RT severity based on those features, provided accuracy 76%. The real-time system designed for efficient extraction of those features and the provision of a continuous RT severity measure is described.
Collapse
Affiliation(s)
- George Rigas
- Department of Computer Science, University of Ioannina, Ioannina GR 45 110, Greece.
| | | | | | | | | |
Collapse
|
27
|
Tsironis C, Stamatis D, Maranis S, Tzika E, Beris A, Konitsiotis S. P2.087 The role of dopamine receptors in the induction of levodopa-induced dyskinesia in parkinsonsian rats. Parkinsonism Relat Disord 2009. [DOI: 10.1016/s1353-8020(09)70438-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
28
|
Astrakas LG, Konitsiotis S, Margariti P, Tsouli S, Tzarouhi L, Argyropoulou MI. T2 relaxometry and fMRI of the brain in late-onset restless legs syndrome. Neurology 2008; 71:911-6. [DOI: 10.1212/01.wnl.0000325914.50764.a2] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
29
|
Kiortsis DN, Tsouli S, Filippatos TD, Konitsiotis S, Elisaf MS. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. Nutr Metab Cardiovasc Dis 2008; 18:207-210. [PMID: 17570651 DOI: 10.1016/j.numecd.2006.10.003] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/29/2006] [Revised: 09/15/2006] [Accepted: 10/05/2006] [Indexed: 11/23/2022]
Abstract
BACKGROUND AND AIM Intentional weight loss results in improvement in mood. Very few data exist regarding the effects of sibutramine on the mood of obese and overweight patients in general clinical samples. Moreover, no study has evaluated the effects of orlistat treatment on mood. The purpose of our study was to assess the effects of sibutramine and orlistat on mood in obese and overweight subjects. METHODS AND RESULTS Sixty obese and overweight women were divided into three groups. The first group (n=20) received a low-calorie diet and sibutramine 10mg; the second group (n=20) received a low-calorie diet and orlistat 120 mg three times a day, and the third group received only the low-calorie diet. CONCLUSION A psychiatric assessment was performed with the Hamilton Depression Rating Scale (HAMD) before and after 3 months of treatment. In all the groups a statistically significant decrease in HAMD scores was observed. However, the decrease in the sibutramine group was greater compared to that observed in the two other groups (P<0.01). These results suggest that sibutramine treatment may improve mood more than diet alone or orlistat therapy in a general clinical sample of obese patients.
Collapse
Affiliation(s)
- D N Kiortsis
- Laboratory of Physiology, Medical School, University of Ioannina, Panepistimiou Avenue, 45110 Ioannina, Greece.
| | | | | | | | | |
Collapse
|
30
|
Hadjigeorgiou GM, Stefanidis I, Dardiotis E, Aggellakis K, Sakkas GK, Xiromerisiou G, Konitsiotis S, Paterakis K, Poultsidi A, Tsimourtou V, Ralli S, Gourgoulianis K, Zintzaras E. Low RLS prevalence and awareness in central Greece: an epidemiological survey. Eur J Neurol 2007; 14:1275-80. [PMID: 17956448 DOI: 10.1111/j.1468-1331.2007.01966.x] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Restless legs syndrome (RLS) is a sensorimotor disorder with a general population prevalence of 3-10%. A single, previous epidemiological study performed in south-east Europe reported the lowest prevalence rate amongst European countries. We conducted a population-based survey of RLS in central Greece. A total of 4200 subjects were randomly recruited. We used the international RLS study group criteria for diagnosis and the severity scale for severity assessment in subjects with RLS. We also included questions to assess the level of awareness of RLS in our region. A total of 3033 subjects were screened. The overall lifetime prevalence was 3.9% with a female-to-male ratio of 2.6:1. Nearly half of RLS patients reported moderate to severe intensity of symptoms. After adjustment for multiple comparisons we found no association of RLS with education level, smoking, alcohol intake, caffeine consumption, shift work, professional pesticide use or comorbid illness. Our study revealed a low level of awareness amongst the population and physicians in our region and sub-optimal management. We provide further evidence for low prevalence of RLS in south-east Europe and a low level of awareness of RLS in our region.
Collapse
Affiliation(s)
- G M Hadjigeorgiou
- Department of Neurology, Medical School of Larissa, University of Thessaly, Larissa, Greece.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Peritogiannis V, Tsouli S, Pappas D, Mavreas V, Konitsiotis S. Neuroleptic malignant syndrome due to amisulpride in a patient with solvent-induced chronic toxic encephalopathy. Clin Neuropharmacol 2007; 30:245-6. [PMID: 17762322 DOI: 10.1097/wnf.0b013e3180cfe3a0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
32
|
Exarchos TP, Tzallas AT, Fotiadis DI, Konitsiotis S, Giannopoulos S. EEG Transient Event Detection and Classification Using Association Rules. ACTA ACUST UNITED AC 2006; 10:451-7. [PMID: 16871711 DOI: 10.1109/titb.2006.872067] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
In this paper, a methodology for the automated detection and classification of transient events in electroencephalographic (EEG) recordings is presented. It is based on association rule mining and classifies transient events into four categories: epileptic spikes, muscle activity, eye blinking activity, and sharp alpha activity. The methodology involves four stages: 1) transient event detection; 2) clustering of transient events and feature extraction; 3) feature discretization and feature subset selection; and 4) association rule mining and classification of transient events. The methodology is evaluated using 25 EEG recordings, and the best obtained accuracy was 87.38%. The proposed approach combines high accuracy with the ability to provide interpretation for the decisions made, since it is based on a set of association rules.
Collapse
Affiliation(s)
- Themis P Exarchos
- Unit of Medical Technology and Intelligent Information Systems, Department of Computer Science, University of Ioannina, Greece.
| | | | | | | | | |
Collapse
|
33
|
Kalambokis G, Konitsiotis S, Pappas D, Tsianos EV. Akinetic mutism followed by a manic reaction on introduction of steroid replacement for Addison's disease. J Endocrinol Invest 2006; 29:257-60. [PMID: 16682841 DOI: 10.1007/bf03345550] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Neuropsychiatric changes during exogenous corticosteroid administration are well-recognized. However, reports of neuropsychiatric reactions to corticosteroid replacement for Addison's disease are distinctively rare. We report on a patient with primary adrenocortical insufficiency, initially presenting with depressive symptoms, who developed akinetic mutism followed by acute manic illness shortly after the initiation of steroid replacement. Both disorders occurred with physiological doses of hydrocortisone and resolved spontaneously. The pathogenesis of the above neuropsychiatric reactions is discussed in the context of glucocorticoid receptor-related brain effects of glucocorticoids. In addition, this report points to the need for accurate psychiatric assessment of patients with Addison's disease upon introduction of replacement therapy.
Collapse
Affiliation(s)
- G Kalambokis
- Department of Internal Medicine Medical School of Ioannina, 45110 Ioannina, Greece
| | | | | | | |
Collapse
|
34
|
Abstract
Levetiracetam (LEV), a novel antiepileptic drug, has demonstrated antidyskinetic effect in preclinical animal models of Parkinson's disease (PD) and in one open label study in PD patients with levodopa-induced dyskinesia. The acute antidyskinetic effects of LEV in patients with tardive dyskinesia were evaluated in an open label study. Eight patients received oral LEV (1,000 mg/day) for 1 month and blinded evaluations were performed at baseline and at the end of the treatment period. A significant reduction of the abnormal movements was recorded while psychiatric symptoms did not worsen and the adverse event profile was benign. LEV may be efficacious for the treatment of tardive dyskinesia and deserves further clinical testing.
Collapse
Affiliation(s)
- Spiros Konitsiotis
- Department of Neurology, University of Ioannina Medical School, Ioannina, Greece.
| | | | | | | |
Collapse
|
35
|
Tzallas AT, Karvelis PS, Katsis CD, Fotiadis DI, Giannopoulos S, Konitsiotis S. A method for classification of transient events in EEG recordings: application to epilepsy diagnosis. Methods Inf Med 2006; 45:610-21. [PMID: 17149502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
OBJECTIVES The aim of the paper is to analyze transient events in inter-ictal EEG recordings, and classify epileptic activity into focal or generalized epilepsy using an automated method. METHODS A two-stage approach is proposed. In the first stage the observed transient events of a single channel are classified into four categories: epileptic spike (ES), muscle activity (EMG), eye blinking activity (EOG), and sharp alpha activity (SAA). The process is based on an artificial neural network. Different artificial neural network architectures have been tried and the network having the lowest error has been selected using the hold out approach. In the second stage a knowledge-based system is used to produce diagnosis for focal or generalized epileptic activity. RESULTS The classification of transient events reported high overall accuracy (84.48%), while the knowledge-based system for epilepsy diagnosis correctly classified nine out of ten cases. CONCLUSIONS The proposed method is advantageous since it effectively detects and classifies the undesirable activity into appropriate categories and produces a final outcome related to the existence of epilepsy.
Collapse
Affiliation(s)
- A T Tzallas
- Dept. of Medical Physics, Medical School, University of Ioannina, Ioannina, Greece
| | | | | | | | | | | |
Collapse
|
36
|
Abstract
In advanced Parkinson's disease, the combination of disease progression and levodopa therapy leads to the development of motor problems complicating the therapeutic response, known as motor response complications. The nonphysiological, pulsatile stimulation produced by most currently available dopaminergic therapies triggers a complicated series of responses resulting in the dysregulation of glutamate receptors and many other neurotransmitter systems on striatal neurons. Although a number of novel compounds that provide a more continuous dopaminergic stimulation are becoming available, no practical way to accomplish this in a truly physiological manner currently exists. Novel strategies for pharmacological intervention with the use of nondopaminergic treatments, with drugs targeting selected transmitter receptors expressed on striatal neurons appear more promising. These include NMDA or AMPA antagonists, or drugs acting on 5-hydroxytryptamine subtype 2A, alpha2-adrenergic, adenosine A2A and cannabinoid CB1 receptors. Future strategies may also target pre- and postsynaptic components that regulate firing pattern, like synaptic vesicle proteins, or nonsynaptic gap junction communication mechanisms, or drugs with actions at the signal transduction systems that modulate the phosphorylation state of NMDA receptors. These new therapeutic strategies, alone or in combination, hold the promise of providing effective control or reversal of motor response complications.
Collapse
Affiliation(s)
- Spiros Konitsiotis
- Department of Neurology, University of Ioannina Medical School, GR-45110, Ioannina, Greece.
| |
Collapse
|
37
|
Pakos EE, Tsekeris PG, Chatzidimou K, Goussia AC, Markoula S, Argyropoulou MI, Pitouli EG, Konitsiotis S. Astrocytoma-like multiple sclerosis. Clin Neurol Neurosurg 2005; 107:152-7. [PMID: 15708234 DOI: 10.1016/j.clineuro.2004.06.003] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2003] [Revised: 04/26/2004] [Accepted: 06/02/2004] [Indexed: 11/30/2022]
Abstract
Multiple sclerosis (MS) may sometimes mimic clinically and radiologically a brain tumor. The initial recognition of such cases is essential as it might avoid a surgical intervention and supplementary treatment. However, even in patients who underwent surgery, the appropriate preparation of the specimen is of crucial importance for the correct pathological diagnosis since tumors and non-neoplastic demyelinating lesions share some common histopathological features. We present such a case of multiple sclerosis presenting with features of an astrocytoma and was treated with surgery and additional radiotherapy.
Collapse
Affiliation(s)
- E E Pakos
- Department of Radiation Therapy, School of Medicine, University Hospital of Ioannina, University of Ioannina, Ioannina 45500, Greece.
| | | | | | | | | | | | | | | |
Collapse
|
38
|
|
39
|
Metafratzi Z, Argyropoulou MI, Mokou-Kanta C, Konitsiotis S, Zikou A, Efremidis SC. Spontaneous intracranial hypotension: morphological findings and CSF flow dynamics studied by MRI. Eur Radiol 2004; 14:1013-6. [PMID: 14605844 DOI: 10.1007/s00330-003-2136-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2003] [Revised: 09/10/2003] [Accepted: 10/01/2003] [Indexed: 10/26/2022]
Abstract
We report on a case of spontaneous intracranial hypotension (SIH) presenting with classic MR findings, such as diffuse smooth thickening and intense contrast enhancement of the dura matter, increased size of the pituitary gland and downward displacement of the brain. In this case an engorgement of the cavernous sinuses is reported as an additional imaging finding of SIH. Moreover, phase-contrast MR study of the CSF flow dynamics revealed at the level of the aqueduct a decrease of the systolic and diastolic flow volume of CSF. A normalization of the flow volume was observed when SIH subsided.
Collapse
Affiliation(s)
- Zafiria Metafratzi
- Department of Radiology, Medical School, University of Ioannina, 45110 Ioannina, Greece
| | | | | | | | | | | |
Collapse
|
40
|
Konitsiotis S, Glantzouni A, Argyropoulou MI, Tsapoga T, Elisaf M, Efremidis SC. Acute spontaneous spinal subdural haematomas in a patient with essential thrombocythaemia. J Neurol 2003; 250:1109-11. [PMID: 14504975 DOI: 10.1007/s00415-003-0125-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2002] [Revised: 03/06/2003] [Accepted: 03/20/2003] [Indexed: 01/13/2023]
|
41
|
Blanchet PJ, Konitsiotis S, Mochizuki H, Pluta R, Emerich DF, Chase TN, Mouradian MM. Complications of a trophic xenotransplant approach in parkinsonian monkeys. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:607-12. [PMID: 12787846 DOI: 10.1016/s0278-5846(03)00048-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Various restorative cell transplantation strategies have been investigated to substitute for lost dopamine (DA) neurons or to enhance DA synthesis in Parkinson's disease. Intracerebral implantation of engineered cells encapsulated in a semipermeable polymer membrane constitutes one way to deliver bioactive substances unable to cross the blood-brain barrier while avoiding the need for long-term immunosuppression. Glial cell line-derived neurotrophic factor (GDNF) has shown trophic effects on DA neurons but effective and sustained delivery within the brain parenchyma remains problematic. The long-term efficacy and late complications of a xenotransplant approach utilizing GDNF-expressing encapsulated baby hamster kidney (BHK) cells were examined. Each of five MPTP-lesioned parkinsonian cynomolgus monkeys received five devices containing active or inert cells grafted bilaterally in the striatum in a two-stage procedure 9 months apart and animals were sacrificed 4 months later for analyses. No definite motor benefit was observed, DA levels were comparable between GDNF- and control cell-implanted striata, and tyrosine hydroxylase (TH) immunoreactivity in the substantia nigra showed no consistent recovery. Cell viability and GDNF synthesis in the explanted devices were negligible. The brain tissue surrounding all implants showed an intense immune reaction with prominent "foreign body" inflammatory infiltrates. Membrane biophysics, the cell type used, and the extended period of time the devices remained in situ may have contributed to the negative outcome and should be addressed in future investigations using this approach.
Collapse
Affiliation(s)
- Pierre J Blanchet
- Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
| | | | | | | | | | | | | |
Collapse
|
42
|
Konitsiotis S, Argyropoulou MI, Kosta P, Giannopoulou M, Efremidis SC, Kyritsis AP. CNS siderosis after brachial plexus avulsion. Neurology 2002; 58:505. [PMID: 11839871 DOI: 10.1212/wnl.58.3.505] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
43
|
Chase TN, Konitsiotis S, Oh JD. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease. Adv Neurol 2002; 86:355-60. [PMID: 11553996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Affiliation(s)
- T N Chase
- Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
| | | | | |
Collapse
|
44
|
Metman LV, Gillespie M, Farmer C, Bibbiani F, Konitsiotis S, Morris M, Shill H, Bara-Jimenez W, Mouradian MM, Chase TN. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol 2001; 24:163-9. [PMID: 11391128 DOI: 10.1097/00002826-200105000-00008] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The objective of the study was to determine the safety and efficacy of increasing doses of Rotigotine CDS in patients with advanced Parkinson's disease. The development of motor complications in Parkinson's disease has been linked to intermittent stimulation of dopamine receptors. Continuous, noninvasive, dopaminergic stimulation has not been available to date. Rotigotine CDS is a lipid-soluble D2 dopamine agonist in a transdermal delivery system that could fill this void. This inpatient study consisted of a 2-week dose escalation phase followed by a 2-week dose maintenance phase at the highest dose (80 cm2). Each individual's L-Dopa dose was back-titrated as feasible. The primary outcome measure was L-Dopa dose, and secondary outcome measures included early morning "off"-L-Dopa Unified Parkinson's Disease Rating Scale motor scores by a blinded evaluator and motor fluctuation data obtained from patient diaries ("on" without dyskinesia, "on" with dyskinesia, and "off"). Seven of 10 subjects provided data that could be evaluated. There were two administrative dropouts, and one individual was eliminated from the study because of recrudescence of hallucinations. The median daily L-Dopa dose decreased from 1,400 to 400 mg (p = 0.018, Wilcoxon test). Unified Parkinson's Disease Rating Scale motor scores were unchanged. Although diary variables improved in most individuals, only the reduction in "off" time attained statistical significance. Adverse effects were mild and consisted mainly of dopaminergic side effects and local skin reactions. The data suggest that Rotigotine CDS is an effective treatment for advanced Parkinson's disease and permits patients to substantially lower L-Dopa doses without loss of antiparkinsonian efficacy. Full-scale controlled clinical trials are warranted. In addition to potential therapeutic benefits, this drug can be used to test the hypothesis that continuous dopaminergic stimulation from the initiation of Parkinson's disease therapy will limit the development of motor complications.
Collapse
Affiliation(s)
- L V Metman
- Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Beris AE, Naka KK, Skopelitou A, Kosta I, Vragalas V, Konitsiotis S, Bontioti E, Soucacos PN. Functional assessment of the rat sciatic nerve following intraoperative expansion: the effect of recovery duration on behavioural, neurophysiological, and morphological measures. Microsurgery 2000; 17:568-77. [PMID: 9431520 DOI: 10.1002/(sici)1098-2752(1996)17:10<568::aid-micr7>3.0.co;2-m] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The purpose of this study was to investigate the feasibility of rapid intraoperative elongation of the rat sciatic nerve with the use of tissue expander and to assess its functional recovery. Out of 51 rats 43 had their right sciatic nerve expanded with a 5-ml intraoperative expander over 1 hr and 8 were sham-operated controls. The functional recovery of the nerve was assessed at intervals up to 4 months using the Sciatic Functional index (SFI), neurophysiological indices, and histology. Intraoperative expansion elongated the rat sciatic nerve by about 13%. SFI decreased on the first postoperative day and started to recover by Day 7, reaching almost preoperative values by Days 14 and 30 according to De Medinaceli and Bain-Mackinnon-Hunter formulas, respectively. Latency and motor conduction velocity demonstrated a deterioration after expansion which peaked on Day 1. Recovery started by Day 7 and reached preoperative levels by 60 days. The histological findings indicated minor aberrations immediately after expansion and maximal demyelination with minimal axonal disruption on Day 1. The reparative process started by Day 7 and continued till Day 120 when almost no histological changes were observed. In conclusion, intraoperative nerve expansion successfully elongates the rat sciatic nerve. It also causes functional and morphological abnormalities which are of low to moderate degree, have a short duration, and are reversible. Intraoperative nerve expansion might be a valuable solution in the treatment of short nerve gaps, but its clinical application still needs to be evaluated.
Collapse
Affiliation(s)
- A E Beris
- Department of Orthopaedic Surgery, University of Ioannina, School of Medicine, Greece
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
OBJECTIVE To evaluate the contribution of amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) glutamate receptors to the pathogenesis of parkinsonian signs and levodopa-induced dyskinesias. BACKGROUND Motor fluctuations and dyskinesias reflect, in part, altered function of glutamate receptors of the NMDA subtype. The possible role of AMPA receptors, however, has not yet been examined. METHODS The authors compared the ability of an AMPA agonist (CX516) and a noncompetitive AMPA antagonist (LY300164) to alter parkinsonian symptoms and levodopa-induced dyskinesia in MPTP-lesioned monkeys. Eight levodopa-treated parkinsonian monkeys received rising doses of each drug, first in monotherapy and then in combination with low-, medium-, and high-dose levodopa. RESULTS CX516 alone, as well as when combined with low-dose levodopa, did not affect motor activity but induced dyskinesia. Moreover, following injection of the higher doses of levodopa, it increased levodopa-induced dyskinesia by up to 52% (p < 0.05). LY300164 potentiated the motor activating effects of low-dose levodopa, increasing motor activity by as much as 86% (p < 0.05), and that of medium-dose levodopa as much as 54% (p < 0.05). At the same time, LY300164 decreased levodopa-induced dyskinesia by up to 40% (p < 0.05). CONCLUSIONS AMPA receptor upregulation may contribute to the expression of levodopa-induced dyskinesia. Conceivably, noncompetitive AMPA receptor antagonists could be useful, alone or in combination with NMDA antagonists, in the treatment of PD, by enhancing the antiparkinsonian effects of levodopa without increasing and possibly even decreasing levodopa-induced dyskinesia.
Collapse
MESH Headings
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
- Animals
- Benzodiazepines/pharmacology
- Benzodiazepines/therapeutic use
- Dioxoles/pharmacology
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Drug Synergism
- Dyskinesia, Drug-Induced/drug therapy
- Dyskinesia, Drug-Induced/metabolism
- Excitatory Amino Acid Antagonists/pharmacology
- Excitatory Amino Acid Antagonists/therapeutic use
- Female
- Levodopa/administration & dosage
- Macaca fascicularis
- Male
- Motor Activity/drug effects
- Parkinson Disease, Secondary/chemically induced
- Parkinson Disease, Secondary/drug therapy
- Piperidines/pharmacology
- Receptors, AMPA/agonists
- Receptors, AMPA/antagonists & inhibitors
- Severity of Illness Index
Collapse
Affiliation(s)
- S Konitsiotis
- Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892-1406, USA
| | | | | | | | | |
Collapse
|
47
|
Abstract
Motor dysfunction produced by the chronic non-physiological stimulation of dopaminergic receptors on striatal medium spiny neurons is associated with alterations in the sensitivity of glutamatergic receptors, including those of the N-methyl-D-aspartate (NMDA) subtype. Functional characteristics of these ionotropic receptors are regulated by their phosphorylation state. Lesioning the nigrostriatal dopamine system of rats induces parkinsonian signs and increases the phosphorylation of striatal NMDA receptor subunits on serine and tyrosine residues. The intrastriatal administration of certain inhibitors of the kinases capable of phosphorylating NMDA receptors produces a dopaminomimetic motor response in these animals. Treating parkinsonian rats twice daily with levodopa induces many of the characteristic features of the human motor complication syndrome and further increases the serine and tyrosine phosphorylation of specific NMDA receptor subunits. Again, the intrastriatal administration of selective inhibitors of certain serine and tyrosine kinases alleviates the motor complications. NMDA receptor antagonists, including some non-competitive channel blockers, act both palliatively and prophylactically in rodent and primate models to reverse these levodopa-induced response alterations. Similarly, in clinical studies dextrorphan, dextromethorphan, and amantadine have been found to be efficacious against motor complications. Recent observations in animal models further indicate that certain amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) antagonists alleviate, while others exacerbate, these complications. Thus, it appears that the denervation or intermittent stimulation of striatal dopaminergic receptors differentially activates signal transduction pathways in medium spiny neurons. These in turn modify the phosphorylation state of ionotropic glutamate receptors and consequently their sensitivity to cortical input. These striatal changes contribute to symptom production in Parkinson's disease, and their prevention or reversal could prove useful in the treatment of this disorder.
Collapse
Affiliation(s)
- T N Chase
- Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke NIH, Bethesda, MD 20892, USA.
| | | | | |
Collapse
|
48
|
|
49
|
Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999; 56:1383-6. [PMID: 10555659 DOI: 10.1001/archneur.56.11.1383] [Citation(s) in RCA: 186] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
BACKGROUND In a recent acute study, amantadine was found to have antidyskinetic effect against levodopa-induced motor complications in patients with Parkinson disease. The longevity of this effect was not addressed but is of interest in light of the controversy in the literature regarding the duration of amantadine's well-established antiparkinsonian action. OBJECTIVE To determine the duration of the antidyskinetic effect of amantadine in advanced Parkinson disease. DESIGN One year after completion of an acute, double-blind, placebo-controlled, crossover study, patients returned for re-evaluation of motor symptoms and dyskinesias using a nonrandomized, double-blind, placebo-controlled follow-up paradigm. SETTING National Institutes of Health Clinical Center. PATIENTS Seventeen of the original 18 patients with advanced Parkinson disease complicated by dyskinesias and motor fluctuations participated in this study; 1 was lost to follow-up. Thirteen of the 17 individuals had remained on amantadine therapy for the entire year. INTERVENTIONS Ten days prior to the follow-up assessment, amantadine was replaced with identical capsules containing either amantadine or placebo. MAIN OUTCOME MEASURES Parkinsonian symptoms and dyskinesia severity were scored using standard rating scales, while subjects received steady-state intravenous levodopa infusions at the same rate as 1 year earlier. RESULTS One year after initiation of amantadine cotherapy, its antidyskinetic effect was similar in magnitude (56% reduction in dyskinesia compared with 60% 1 year earlier). Motor complications occurring with the patients' regular oral levodopa regimen also remained improved according to the Unified Parkinson's Disease Rating Scale (UPDRS-IV). CONCLUSION The beneficial effects of amantadine on motor response complications are maintained for at least 1 year after treatment initiation.
Collapse
Affiliation(s)
- L V Metman
- Experimental Therapeutics Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD 20892-1406, USA
| | | | | | | | | | | |
Collapse
|
50
|
Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther 1999; 290:1034-40. [PMID: 10454475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023] Open
Abstract
The antiparkinsonian and antidyskinetic profile of two N-methyl-D-aspartate (NMDA) receptor antagonists, a competitive antagonist, (R)-4-oxo-5-phosphononorvaline (MDL 100,453), and a novel noncompetitive allosteric site antagonist, 4-hydroxy-N-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piper idi ne (Co 101244/PD 174494), was assessed in six levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine-lesioned parkinsonian monkeys. The effects on motor function of these two drugs, alone and in combination with levodopa, were then correlated with NMDA subtype selectivity and apparent affinity for four diheteromeric NMDA receptor subunit combinations expressed in Xenopus oocytes. MDL 100, 453 (300 mg/kg s.c.) by itself increased global motor activity (p =. 0005 versus vehicle) and administered 15 min after a low dose of levodopa/benserazide s.c., MDL 100,453 (50, 300 mg/kg s.c.) showed dose-dependent potentiation of antiparkinsonian responses and also produced dyskinesias. Following injection of a fully effective dose of levodopa, MDL 100,453 (300 mg/kg s.c.) also produced a 25% increase in mean dyskinesia score (p =.04). In contrast, Co 101244 did not change motor activity by itself and only showed a tendency to potentiate the antiparkinsonian response when given in combination with a low dose of levodopa, which did not attain statistical significance. However, with a high dose of levodopa, Co 101244 (0.1, 1 mg/kg s.c.) displayed antidyskinetic effects (67 and 71% reduction, respectively) while sparing levodopa motor benefit. In vitro, MDL 100,453 was an NMDA glutamate-site antagonist, with approximately 5- to 10-fold selectivity for the NR1A/NR2A subtype combination (K(b) = 0.6 microM) versus NR1A in combination with 2B, 2C, or 2D. In contrast, the allosteric site antagonist Co 101244 showed approximately 10,000-fold selectivity for the NR1A/NR2B (IC(50) = 0.026 microM) versus the other three subunit combinations tested. Taken together, the data suggest that the NR2 subunit selectivity profile of NMDA receptor antagonists can play an important role in predicting behavioral outcome and offer more evidence that NR2B-selective NMDA receptor antagonists may be useful agents in the treatment of Parkinson's disease.
Collapse
Affiliation(s)
- P J Blanchet
- Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
| | | | | | | | | | | |
Collapse
|